<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=30053"><dc:title>Remission is maintained after switch from dose-optimised intravenous treatment to subcutaneous treatment with vedolizumab in inflammatory bowel disease</dc:title><dc:creator>Pintar,	Špela	(Avtor)
	</dc:creator><dc:creator>Hanžel,	Jurij	(Avtor)
	</dc:creator><dc:creator>Drobne,	David	(Avtor)
	</dc:creator><dc:creator>Koželj,	Matic	(Avtor)
	</dc:creator><dc:creator>Kurent,	Tina	(Avtor)
	</dc:creator><dc:creator>Smrekar,	Nataša	(Avtor)
	</dc:creator><dc:creator>Novak,	Gregor	(Avtor)
	</dc:creator><dc:subject>inflammatory bowel disease</dc:subject><dc:subject>Crohn’s disease</dc:subject><dc:subject>ulcerative colitis</dc:subject><dc:subject>vedolizumab</dc:subject><dc:subject>subcutaneous formulation</dc:subject><dc:date>2024</dc:date><dc:date>2026-06-12 12:33:54</dc:date><dc:type>Neznano</dc:type><dc:identifier>30053</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>